Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.49 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PADI4 | Q9UM07 | 4/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25017554 | 1.00 | USP30 (0.49) | USP30ANO1HDAC4HDAC6PARP1 | |
| SCHEMBL28583314 | 0.92 | USP30 (0.46) | USP30HDAC4PARP1F10 | |
| SCHEMBL25016107 | 0.87 | F10 (0.41) | USP30F10 | |
| SCHEMBL25017557 | 0.87 | KDM4E (0.44) | USP30F10 | |
| SCHEMBL25016295 | 0.86 | USP30 (0.41) | USP30PARP1PADI4 | |
| SCHEMBL25016100 | 0.86 | USP30 (0.41) | USP30PARP1PADI4 | |
| SCHEMBL25017943 | 0.85 | ACHE (0.43) | HDAC6F10 | |
| SCHEMBL25015770 | 0.85 | KDM4E (0.49) | ACKR3F10 | |
| SCHEMBL25015886 | 0.83 | F10 (0.43) | F10 | |
| SCHEMBL25015739 | 0.81 | CYP3A4 (0.38) | USP30PADI4F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | USP30 2653/4885ANO1 2217/4885HDAC4 3500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.